Skip to search formSkip to main contentSkip to account menu

Fentanyl Citrate-containing Nasal Spray

Known as: Intranasal Fentanyl Spray 
A nasal spray containing a phosphate-buffered solution of the citrate salt form of fentanyl, a short-acting, synthetic, lipophilic anilidopiperidine… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Efficiency of Intranasal Fentanyl in Patients with Breakthrough Cancer Pain in Daily Practice - Results of the German Non-Interventional Study with Instanyl® (GENISIS)
Objective: Breakthrough cancer pain (BTcP) affects 19-95% of cancer patients (dependent on the definition and methods used and… 
2013
2013
An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects.
BACKGROUND Intranasal Fentanyl Spray (INFS) was developed for the treatment of breakthrough pain (BTP) in cancer patients using a… 
Review
2012
Review
2012
Intranasal Fentanyl Spray: A Novel Dosage Form for the Treatment of Breakthrough Cancer Pain
Objective: To review the pharmacology, pharmacokinetics, clinical efficacy, adverse events, dosing, and administration of… 
Review
2011
Review
2011
Newer Generation Fentanyl Transmucosal Products for Breakthrough Pain in Opioid-Tolerant Cancer Patients
Oral normal-release morphine has long been considered the gold-standard treatment for cancer breakthrough pain. However, its… 
Review
2011
Review
2011
Fentanyl nasal spray for the treatment of cancer pain
Introduction: Breakthrough pain, a transitory flare of pain in patients with otherwise controlled chronic pain, has been well… 
2010
2010
Breakthrough cancer pain and current treatment options
2009
2009
719 PHARMACOKINETICS OF INTRANASAL FENTANYL SPRAY (INFS) IN SUBJECTS WITH COMMON COLD
2009
2009
718 PHARMACOKINETICS OF INTRANASAL FENTANYL SPRAY (INFS) IN SUBJECTS WITH SEASONAL ALLERGIC RHINITIS WITH AND WITHOUT PRIOR ADMINISTRATION OF OXYMETAZOLINE
2009
2009
685 EFFICACY OF INTRANASAL FENTANYL SPRAY (INFS) VERSUS ORAL TRANSMUCOSAL FENTANYL CITRATE (OTFC) FOR BREAKTHROUGH CANCER PAIN: OPEN‐LABEL CROSSOVER TRIAL
2009
2009
717 HIGHER SYSTEMIC BIOAVAILABILITY AND FASTER ABSORPTION OF INTRANASAL FENTANYL SPRAY (INFS) COMPARED TO ACTIQ® (OTFC) IN HEALTHY SUBJECTS
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)